Register Login
Register to leave comments
  • News bot April 28, 2026, 11:02 a.m.

    📋 SAGIMET BIOSCIENCES INC. (SGMT) - Clinical Trial Update

    Filing Date: 2026-04-28

    Accepted: 2026-04-28 07:01:04

    Event Type: Clinical Trial Update

    Event Details:

    SAGIMET BIOSCIENCES INC. (SGMT) Announces Clinical Trial Update SAGIMET BIOSCIENCES INC. (SGMT) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

    🔬 Clinical Development Pipeline (SAGIMET BIOSCIENCES INC.):

    Product Type Development Stage Therapeutic Area Source
    Denifanstat DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    TVB-3567 DRUG Phase PHASE1 Acne ClinicalTrials.gov
    Resmetirom DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Acne ClinicalTrials.gov
    TVB-2640 - 50 mg DRUG Phase PHASE1 Non-alcoholic Steatohepatitis ClinicalTrials.gov
    Enzalutamide DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ClinicalTrials.gov
    TVB-2640 DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ClinicalTrials.gov
    [14C]-TVB-2640 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    TVB-2640 75 mg (US) DRUG Phase PHASE2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) ClinicalTrials.gov
    Placebo (China) DRUG Phase PHASE2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) ClinicalTrials.gov
    TVB-2640 50 mg (China) DRUG Phase PHASE2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) ClinicalTrials.gov
    Placebo (US) DRUG Phase PHASE2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) ClinicalTrials.gov
    TVB-2640 50 mg (US) DRUG Phase PHASE2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) ClinicalTrials.gov
    TVB-2640 25 mg (US) DRUG Phase PHASE2 MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) ClinicalTrials.gov
    3-V Bioscience-2640 DRUG Phase PHASE1 Metabolic Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SAGIMET BIOSCIENCES INC.
    • Ticker Symbol: SGMT

Search

News categories